论文部分内容阅读
采用随机分组方法，比较康莱特注射液治疗１０５例原发性肝癌（观察组）与化疗治疗５１例原发性肝癌（对照组）的临床疗效及毒副作用。结果显示，观察组癌灶缓解率（ＣＲ＋ＰＲ）为１１４２％；对照组为９８０％；同时观察组可明显改善原发性肝癌患者的临床主要症状，症状改善总有效率为８０９５％，可提高患者生存质量。还可提高ＮＫ细胞活性及ＣＤ４／ＣＤ８比值，对外周血象及肝肾功能无明显影响。观察组中脾虚湿困型及热毒型疗效最佳。不良反应有发热、恶心、头晕、静脉炎。
Randomized grouping method was used to compare the clinical efficacy and side effects of Kanglaite injection in the treatment of 105 cases of primary liver cancer (observation group) and chemotherapy treatment of 51 cases of primary liver cancer (control group). The results showed that the remission rate (CR+PR) of the observation group was 11 42%, and that of the control group was 9 80%. At the same time, the observation group could significantly improve the clinical symptoms of primary liver cancer patients. The total effective rate of symptom improvement was 80 . 95% can improve the quality of life of patients. It also increased NK cell activity and CD4/CD8 ratio, and had no significant effect on peripheral blood and liver and kidney function. In the observation group, the spleen deficiency type and the hot-toxic type were the best. Adverse reactions are fever, nausea, dizziness, and phlebitis.